“Strategic M&A and licensing deals are therefore inevitable for innovation starved drug/biotech companies looking for growth in a highly competitive and global marketplace.
Given that it takes several years and millions of dollars to develop new therapeutics from scratch, large pharmaceutical companies sitting on huge piles of cash may prefer to buy innovative small/mid cap biotech companies to build out their pipelines.”
Thanks for the article. I especially love this line: “ What matters for companies looking to buy a drug/biotech stock is the current sales performance of the latter's drugs/products, prospects of sales growth, and the quality of the pipeline.”
I don’t see anything there about the price of their stock. But then the FUDsters already know that don’t they.
News 
Market Data 
Discover 
